| XLS |
|
|
|
|
| ||
|
€ million |
Note |
2012 |
2011 | ||
| |||||
|
Profit after tax |
|
579.0 |
618.01 | ||
|
Depreciation / amortization / impairment losses / write-ups |
|
1,396.6 |
1,597.4 | ||
|
Changes in inventories |
|
140.6 |
–75.3 | ||
|
Changes in trade accounts receivable |
|
186.2 |
–3.7 | ||
|
Changes in trade accounts payable |
|
198.8 |
–119.3 | ||
|
Changes in provisions |
|
378.6 |
–418.71 | ||
|
Changes in other assets and liabilities |
|
–383.5 |
–150.01 | ||
|
Neutralization of gain / loss on disposals of assets |
|
–31.6 |
–208.8 | ||
|
Other non-cash income and expenses |
|
7.5 |
31.6 | ||
|
Net cash flows from operating activities |
[55] |
2,472.2 |
1,271.2 | ||
|
|
|
|
| ||
|
Investments in intangible assets |
|
–144.2 |
–79.7 | ||
|
Investments in property, plant and equipment |
|
–329.1 |
–366.3 | ||
|
Acquisitions |
|
–20.6 |
–161.0 | ||
|
Investments in non-current financial assets |
|
–42.4 |
–10.5 | ||
|
Disposal of non-current assets |
|
93.6 |
787.4 | ||
|
Purchase / sale of marketable securities |
|
10.4 |
–4.7 | ||
|
Changes in other financial assets |
|
–725.6 |
–1,061.2 | ||
|
Net cash flows from investing activities |
[56] |
–1,157.9 |
–896.0 | ||
|
|
|
|
| ||
|
Dividend payments |
|
–102.6 |
–86.8 | ||
|
Profit transfers to E. Merck KG and changes in reserves |
|
–304.5 |
–326.5 | ||
|
Payments from transactions with no change of control |
|
–15.0 |
– | ||
|
Changes in liabilities to E. Merck KG |
|
10.6 |
77.3 | ||
|
Repayment of bonds |
|
–1,000.0 |
–20.8 | ||
|
New borrowings of other current and non-current financial liabilities |
|
37.5 |
16.8 | ||
|
Repayments of other current and non-current financial liabilities |
|
–145.4 |
–44.1 | ||
|
Net cash flows from financing activities |
[57] |
–1,519.4 |
–384.1 | ||
|
|
|
|
| ||
|
Changes in cash and cash equivalents |
|
–205.1 |
–8.9 | ||
|
Changes in cash and cash equivalents due to currency translation |
|
–3.0 |
1.8 | ||
|
Cash and cash equivalents as of January 1 |
|
937.8 |
943.7 | ||
|
Cash and cash equivalents as of December 31 |
|
729.7 |
936.6 | ||
|
Plus cash and cash equivalents included in assets held for sale |
|
– |
1.2 | ||
|
Cash and cash equivalents as of December 31 (consolidated balance sheet) |
[37] |
729.7 |
937.8 | ||